am 251 has been researched along with Hypothyroidism in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Veiga, MA | 1 |
| Fonseca Bloise, F | 1 |
| Costa-E-Sousa, RH | 1 |
| Souza, LL | 1 |
| Almeida, NA | 1 |
| Oliveira, KJ | 1 |
| Pazos-Moura, CC | 1 |
1 other study available for am 251 and Hypothyroidism
| Article | Year |
|---|---|
Acute effects of endocannabinoid anandamide and CB1 receptor antagonist, AM251 in the regulation of thyrotropin secretion.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Endocannabinoids; Hyperthyroidism; Hypo | 2008 |